Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine that panitumumab will have clinically meaningful
anti-tumor activity in patients with metastatic colorectal cancer who have developed
progressive disease or relapsed while on or after prior fluoropyrimidine, irinotecan and
oxaliplatin chemotherapy.